Monitoring recombinant activated factor VII (rFVIIa) treatment outcomes remains challenging. Thromboelastography (TEG) and the thrombin generation assay (TGA), measure coagulation dynamics over time and are being assessed as potential methods for evaluat- rFVIIa in a non-bleeding state. For TEG, kaolin and tissue factor were used as activators;
as effective as three consecutive doses of 90 μg kg −1 . 3, 4 While rFVIIa provides high efficacy rates, [3] [4] [5] [6] [7] monitoring treatment outcomes remains challenging: the relationship between FVIIa clot activity and clinical efficacy is unclear and there are currently no validated, standardized assays to measure in vivo efficacy of rFVIIa or predict individual patient response. 8, 9 Global haemostatic assays, such as thromboelastography (TEG) and the thrombin generation assay (TGA), measure coagulation dynamics over time [8] [9] [10] and are being assessed as possible methods for evaluating and monitoring haemophilia treatment. 10, 11 However, lack of standardized TEG/TGA assay methods hinders result comparisons between laboratories/trials and establishing a correlation with outcomes in clinical trials. 10 For TEG, the choice of activators varies among studies and research centres, as well as diseases and treatments studied, with both intrinsic (using kaolin) 12, 13 and extrinsic activation (using tissue factor [TF]) 10, 12, 14, 15 described in the literature. For TGA, both platelet-rich (PRP) and platelet-poor (PPP) plasma have been used 10, 16 ; the use of fresh or frozen plasma is another variable to consider, 16 along with the addition of contact activation inhibitors such as corn trypsin inhibitor (CTI). 10 The trial's aims were to compare pharmacokinetics (PK) of rFVIIa after multiple doses (3×90 μg kg ) in haemophilia patients and evaluate TEG and TGA results postdosing to determine how these global assays relate to the observed PK findings. TEG/ TGA methods were selected on the basis of an earlier evaluation, which determined the most suitable assay conditions for monitoring rFVIIa.
| MATERIALS AND METHODS

| Patients
Adult males (≥18 years) with severe congenital haemophilia A or B (<1% FVIII/FIX) with/without inhibitors were eligible. Key exclusion criteria were the presence of any other congenital or acquired coagulation disorder, clinical signs/known history of arterial thrombotic events and history of deep vein thrombosis or pulmonary embolism.
Written informed consent was obtained from all patients.
| Trial design
This was an open-label, single-centre, randomized, crossover trial. Patients received a single intravenous (IV) injection of rFVIIa 270 μg kg −1 crossed over with three 90 μg kg −1 (every three hours
[q3h]) IV injections in a non-bleeding state. The two dosing regimens were administered in a randomized order at least 48 hours, and no more than 4 weeks, apart ( Figure 1 ). Prior to administration, all patients completed a 3-, 5-or 2-day washout period from the last FVIII 
| Pharmacokinetic analysis
The PK of single-dose (270 μg kg 
| Pharmacodynamic assessment
| Evaluation of optimal TEG/TGA assay conditions
Earlier ex vivo and in vivo studies were conducted in patients to assess optimal TEG/TGA assay conditions for monitoring rFVIIa treatment (see Supplementary Material). When evaluating rFVIIa administration response by TEG, kaolin activation is preferable to activation by TF+tissue plasminogen activator (tPA), as it is simpler and more reproducible. 10 TF needs to be diluted several-fold and this can cause variability in the results, which make comparison difficult. When TGA is used to evaluate rFVIIa treatment response, frozen PRP without CTI should be the preferred method as it provides better correlation between TGA parameters and FVIIa activity (vs frozen PPP). Therefore, for the current study, kaolin was chosen for TEG analysis of rFVIIa treatment, and frozen PRP without CTI was chosen for TGA evaluation of treatment response.
| Thromboelastography
The TEG assay was performed at the trial site in Spain (Hospital Universitario La Paz). The analyses were performed on TEG 
| Thrombin generation
This was measured using the Calibrated Automated Thrombogram 
| Other coagulation-related parameters
| Blood sampling
Blood samples for PK analysis of single-dose rFVIIa were collected predose and 10 minute, 1, 3, 6, 9, 12 and 24 hours postdose. For PK analysis of the 3×90 μg kg −1 regimen, samples were collected predose and 10 minutes, 1 and 3 hours, 3 hours 10 minutes (10 minutes after second administration), 6 hours, 6 hours 10 minutes (10 minutes after third administration) and 7, 9, 12 and 24 hours after the first dose.
Sample collection for the TEG/TGA assays was performed at the same time points, except for the 1-and 12-hour time points.
| Data analyses
PK analysis was performed using non-compartmental methods (SAS 
| Safety
All patients were monitored for adverse events (AEs). 
| RESULTS
| Patients
| Pharmacokinetics
PK profiles and parameters ( Figure 2 ; , respectively, and the estimated half-life for each was 2.86 and 2.61 hours, respectively ( Table 2 ). The accumulation ratio was 1.8, based on area under the plasma concentration-time curve for the multiple-dose regimen (AUC 0-3 hours third dose divided by AUC 0-3 hours first dose), with higher peak levels (73.2 IU mL (Table 2 ). This is as expected and caused by complex formation between rFVIIa and antithrombin (AT), the main clearance pathway for rFVIIa, as the FVII antigen assay does not distinguish between active and AT-bound FVII. TEG profiles for both regimens show that blood is able to form a clot in the assay up to 9 hours after the first rFVIIa dose.
| Thrombin generation
Intra-and inter-patient differences were also evident with the T A B L E 2 Pharmacokinetic profile parameters for single-dose (270 μg kg 
| Coagulation-related parameters
The results for the coagulation-related parameters PT, aPTT, F1+2
and D-dimers are shown in Figure 6 . For F1+2, a delayed response to rFVIIa dosing was seen compared with FVIIa activity, with peak concentration measured 1 hour after administration. 
| Safety
Four non-serious AEs in four patients were reported: dizziness, lingual itching, superficial haematoma and trauma-related bleeding. All
AEs were mild and not considered by the Investigator to be related to rFVIIa. There were no deaths, serious AEs or AEs leading to withdrawal. No other significant safety issues were identified. . Both TEG and TGA showed some differences between single-and multiple-dose rFVIIa; both supported the PK results, as clot formation and thrombin generation were observed for FVIIa activity levels >15-20 IU mL
| DISCUSSION
. We performed the TGA with frozen PRP, as the presence of platelets in the sample allows the haemostatic effect of rFVIIa to be captured more effectively. Both ETP and peak thrombin concentration were sensitive to FVIIa activity level and showed higher values for a single dose than for the first dose in the multiple-dose regimen, suggesting that 270 μg kg −1 has a higher haemostatic potential than obtained after each 90 μg kg
dose. The ETP and peak thrombin profiles over time also correlated with PK profiles, showing a reduction in thrombin generation correlating to PK trough levels; there were some outliers in TGA parameter profiles, but this was due to lost samples. These findings may support use of a single rFVIIa dose when a faster haemostatic response is needed, but additional clinical data are necessary. TEG data showed a FVIIa level-dependent effect but was incapable of depicting differences between single-and multiple-regimen doses. MTG response showed an activity-dependent decline with a 270 μg kg −1 single dose, whereas repeated doses of 90 μg kg -1 maintained almost unvariable MTG for up to 9 hours, suggesting a "carry over" effect. Therefore, when using a single dose of rFVIIa, additional doses may be needed after 6-9 hours to maintain activity levels at around 20 IU mL to treatment in patients without inhibitors. 30 In this latter study, only 
| CONCLUSION
The TGA, performed using frozen PRP without CTI, showed a dosedependent effect of rFVIIa on thrombin generation; TEG using kaolin activation revealed lower dose-dependent effects. While TEG and 
